ABSTRACT. We determined the alleles of ten single nucleotide polymorphisms (SNPs) in the APOA5/A4/C3/A1 gene cluster and in APOB in Han Chinese from Xinjiang Shihezi, China using MALDI-TOF mass spectrometry, and explored the correlation between these SNPs and dyslipidemia through a case-control study design with 250 patients and 250 normal controls. All SNPs except for APOA5 rs2072560 conformed to Hardy-Weinberg equilibrium (all P > 0.05). APOA5 rs651821, APOA4 rs5104, APOC3 rs734104, and APOC3 rs5128 genotype and allele frequencies were significantly different between groups (all P < 0.01). For rs651821, the risks of dyslipidemia for the CC or H.J. Ou et al.
INTRODUCTION
Supernormal increase of one or more of lipids in plasma is called hyperlipidemia (Zheng and Zhu 2007) , and can include total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), and high density lipoprotein cholesterol (HDL-C). The first three are characterized by increased levels, whereas the latter becomes reduced. Recently, studies have found that the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms were associated with dyslipidemia, but these findings have been controversial (Dallongeville et al., 2006; Chien et al., 2008; Yin et al., 2011; Zhang et al., 2011) . Important reasons for the discrepancies might be related to the limitations of the research studies to a single or a small number of single nucleotide polymorphisms (SNPs), and the relatively weak associations detected. Xinjiang Shihezi Han Chinese originate from all over China, and represent the Han people. We chose ten SNPs that had controversial results as well as relatively high mutation rates within the APOA5/A4/C3/A1 gene cluster and the APOB gene. The purpose of our analysis was to reveal the genetic correlation of dyslipidemia, and to provide new opportunities for the prevention and treatment of cardiovascular disease.
MATERIAL AND METHODS

Ethical approval
This study was approved by the Ethics Committee of The First Affiliated Hospital of Shihezi University and adhered to the standards of the Declaration of Helsinki. All participants provided written informed consent.
Subjects
The patients and controls were recruited from the First Affiliated Hospital of Medical College, Shihezi University (ShiHeZi, China); after obtaining informed consent and ethical approval, 500 subjects participated in this study. Inclusion criteria were taken from China's Prevention and Cure Guide of Hypertension (Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults, 2007) . Characteristics of the dyslipidemia group were: TG ≥ 2.26 mM, TC ≥ 6.22 mM, LDL-C ≥ 4.14 mM, and HDL-C < 1.04 mM; and of the control group were: TG < 1.7 mM, TC < 5.18 mM, LDL-C < 3.37 mM, and HDL-C ≥ 1.04 mM. Individuals who had thyroid disease, malignant tumor, tuberculosis, multiple organ failure, or had used lipid-lowering drugs within one week prior to admission were excluded from the study.
Biochemical analyses
Venous blood samples (3 mL) were collected from each subject into tubes containing Heparin after 12 h overnight fasting. TC, TG, LDL-C, and HDL-C levels were measured using standard methods using an OLYAMPUS2700 automatic biochemical analyzer (Olympus Co. Ltd., Tokyo, Japan).
Selection of SNPs and primer design
A total of ten SNPs from five genes were selected using the HapMap database as a reference. Based on the specific RS number of each SNP locus, 10 groups of primers with a perfect match were designed using the MassARRAY Assay Design software (Sequenom Inc., San Diego, CA, USA). To avoid cross hybridization, no short tandem repeats were included within the hybridization sequence. Three primers were designed for each SNP, including a pair of primers for polymerase chain reaction (PCR) amplification and a single-base extension primer ( Table 1 ). The primers were synthesized by the Shanghai Sangon Biological Engineering Technology Corporation (Shanghai, China).
Genotyping
DNA extraction: To determine the allele frequencies of the SNPs, blood samples were collected from 487 unrelated Han Chinese individuals. DNA was extracted from 0.3 mL blood using the RelaxGene Blood DNA System (BeiJing TIANGEN Co. Ltd., Beijing, China). The extracted DNA was qualitatively assessed using 1% agarose gel electrophoresis and quantified using UV spectrophotometry; concentrations were in the range of 10-30 ng/mL.
Multiplex PCR: PCRs were performed in 5 mL total volume, containing 1.6 μL nuclease free water, 0.5 μL 10X PCR buffer with 20 mM MgCl 2 , 0.4 μL 25 mM MgCl 2 , 0.1 μL 25 mM dNTP mix, and 0.2 μL 5 U/μL PCR enzyme (all from Sequenom Inc.). The PCR conditions were as follows: 94°C for 4 min, followed by 45 cycles of 94°C for 20s, 56°C for 30s, 72°C for 1 min, and a final step of 72°C for 3 min. The samples were kept at 4°C until further analysis.
Shrimp alkaline phosphatase (SAP) dephosphorylation: After the PCRs were performed, the products of three reactions were treated with SAP to remove excess dNTPs. This reaction contained 0.3 μL 1.7 U/μL SAP enzyme, 0.17 μL 10X SAP buffer, and 1.53 μL nuclease free water (all from Sequenom Inc.). The reaction conditions were 37°C for 40 min and 85°C for 5 min, and the samples were kept at 4°C until further analysis.
Primer extension reactions: The PCR products were then used as templates for primer extension reactions using the iPlex1 Gold reagent kit (Sequenom Inc.). The extension reactions were performed in 9 mL final volume, which contained 0.2 μL 10X iPlex Buffer plus, 0.2 μL iPlex terminator, 0.041 μL iPlex enzyme (Sequenom Inc.), 0.94 μL primer mix, and 0.619 μL nuclease free water. The extension reaction conditions were as follows: 94°C for 30 s, followed by 40 cycles of 94°C for 5 s, followed by 5 cycles of 52°C for 5 s and 80°C for 5 s and a final step of 72°C for 3 min. The samples were kept at 4°C until further analysis.
MALDI-TOF mass spectrometry (MS): Cleaned PCR products were spotted onto a MassARRAY SpectroCHIP with an auto-spot arm (Sequenom Inc.) and air-dried. The target plate was then inserted into the MALDI-TOF mass spectrometer of the MassARRAY Compact System (Sequenom Inc.), and the analysis was performed using 1800 nitrogen laser shots for each sample. The mass range of the MS instrument was set at 3920-12,023 Da.
Statistical analysis
The data were analyzed with the statistical software package SPSS 17.0 (SPSS, Chicago, IL, USA). Quantitative variables are reported as means ± standard deviation, and differences among two groups were analyzed with an independent sample t-test. Qualitative variables are reported as percentages. Hardy-Weinberg equilibrium was assessed by χ 2 analysis. Analyses of genotype and allele distributions were obtained using the χ 2 test or single factor 
RESULTS
Subject characteristics
According to inclusion and exclusion criteria, 500 subjects were selected for the research program, and experimental results of 487 people were completed. There was no difference in age, gender, body mass index (BMI), smoking, drinking, hypertension, or diabetes between the two groups. Serum TC, TG, LDL-C, and HDL-C levels were significantly different between dyslipidemia and control groups (P < 0.05). General data are shown in 
Hardy-Weinberg equilibrium
We utilized the TYPER 4.0 software (Sequenom) to automatically output classification results. The observed allele frequencies for the Han Chinese population are presented in Figures 1-10 . In the dyslipidemia and control groups, only rs2072560 deviated from HardyWeinberg equilibrium (P < 0.05).
Genotype and allele frequencies
The genotype and allele frequencies observed for the dyslipidemia and control groups are presented in Table 3 . Only four (APOA5 rs651821, APOA4 rs5104, APOC3 rs734104, APOC3 rs5128) SNPs showed differences in distributions between the two groups.
Relationship between rs651821, rs5104, rs734104, rs5128, and dyslipidemia
For APOA5 rs651821, the risks of dyslipidemia associated with carrying the CC or CC+CT genotypes were 9.917 or 1.859 times than of the TT genotype, respectively, and the risk of dyslipidemia for carriers of the C allele was 2.027 times that of the T allele. For APOA4 rs5104, the risks of dyslipidemia for the AG, GG, or AG+GG genotypes were 1.797, 1.861 or 1.809 times that of the AA genotype, and the risk of dyslipidemia for the G allele was 1.427 times that of the A allele. For APOC3 rs734104, the risks of dyslipidemia for the CT, CC, or CC+CT genotypes were 1.851, 2.570, or 1.958 times that of the TT genotype, and the risk of dyslipidemia from the C allele was 1.610 times that of the T allele. For APOC3 rs5128, the risks of dyslipidemia for the GC or CC+GC genotypes were 1.738 or 1.749 times that of the GG genotype, and the risk of dyslipidemia for the C allele was 1.477 times that of the G allele (Table 4) . *P value shows genotype frequency differences in the distribution of the two groups. # P value shows allele frequency differences in the distributions of the two groups. SNP = single nucleotide polymorphism. Table 5 . Haplotype analysis of dyslipidemia and control groups. : rs651821T, rs5104A, rs734104T, rs5128G. CGCC: rs651821C, rs5104G, rs734104C, rs5128C. TGCC: rs651821T, rs5104G, rs734104C, rs5128C. CATG: rs651821C, rs5104A, rs734104T, rs5128G. TACC: rs651821T, rs5104A, rs734104C, rs5128C. TGTG: rs651821T, rs5104G, rs734104T, rs5128G. TATG: rs651821T, rs5104A, rs734104T, rs5128G. TATG: rs651821T, rs5104A, rs734104T, rs5128G. CGCG: rs651821C, rs5104G, rs734104C, rs5128G. TATC: rs651821T, rs5104A, rs734104T, rs5128C . *Compared with TATG. OR = odds ratio; CI = confidence interval.
TATG
Haplotype analysis
To examine the combined effect of the four SNPs (in the order of rs651821, rs5104, rs734104, and rs5128) in dyslipidemia, we conducted haplotype analysis with these SNPs on the serum lipid traits shown in Table 5 . There were 16 haplotypes in our population. We combined the eight haplotypes with frequencies less than 4 into one group; the other eight haplotype analyses are shown in Table 5 . The risks of dyslipidemia with the CGCC [odds ratio (OR) = 2.434], TGCC (OR = 1.503), or CATG (OR = 2.740) haplotypes were significantly higher than that of the wild-type haplotype TATG (P < 0.05).
DISCUSSION
Recently, researchers across the world have examined the relationship between single SNPs in the APOA5/A4/C3/A1 gene cluster or the APOB gene and dyslipidemia, but the results have not been completely compatible. Tan et al. (2012) found that the rs651821 C allele frequency was 27% in Han male of Guigang, China. The result of this study suggested that the C allele presented a risk factor for dyslipidemia; these results were consistent to those from our research study. Our results suggested that the rs651821 C allele frequencies in the dyslipidemia and control groups were 35.48 and 25.34%, respectively, and that the C allele posed a risk factor for dyslipidemia, as the risk incidence increased 2.027 times in individuals carrying the C allele. Brautbar et al. (2011) found that the rs651821 C allele frequency was 9% in 2228 patients with mixed dyslipidemia in the United States; this finding was inconsistent with our results, most likely due to racial diversity between studies. Liu et al. (2009) found that the rs5104 G allele frequency was 13% in a population of European descent, and that this allele was associated with serum TG levels. We found that the rs5104 G allele frequencies were 39 and 30.28% in the dyslipidemia and control groups, respectively, and that the risk incidence increased 1.861 times in individuals with the GG genotype.
In 553 Inuit people, Rudkowska et al. (2013) found that the rs5128 C allele frequency was 56.05%; however, we found that the rs5128 C allele frequency was 36.31%. Bhanushali and Das (2010) found that rs5128 was associated with dyslipidemia from a study in the Indian population. The result of our research were identical to theirs. We suggest that the detected allele frequencies differed as a result of different ethnic groups, but that the effects on blood lipid mechanism is likely to be consistent.
Worldwide, there have been few reports about the correlation of rs734104 C alleles and dyslipidemia. It is therefore very important and necessary to examine many SNPs, and especially to perform haplotype analysis to determine the association of the APO genes with dyslipidemia. Relative to the results obtained from examination of a single SNP, the relationships detected between haplotypes and blood lipids appear to be stronger and of higher significance.
This study found that the relative risk of dyslipidemia associated with the CGCC, TGCC, and CATG haplotypes was particularly high. Considering that only rare reports exist regarding the correlation of these haplotypes with dyslipidemia, further research should be performed in this area and on different populations.
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